BTAI:NSD-BioXcel Therapeutics Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 22.57

Change

+1.62 (+7.73)%

Market Cap

USD 0.63B

Volume

0.21M

Avg Analyst Target

USD 24.00 (+6.34%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BioXcel Therapeutics Inc (BTAI) Stock Analysis:
Based on the BioXcel Therapeutics Inc stock forecasts from 4 analysts, the average analyst target price for BioXcel Therapeutics Inc is USD 24.00 over the next 12 months. BioXcel Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of BioXcel Therapeutics Inc is Bearish, which is based on 1 positive signals and 3 negative signals. At the last closing, BioXcel Therapeutics Inc’s stock price was USD 22.57. BioXcel Therapeutics Inc’s stock price has changed by -0.36 % over the past week, -11.67 % over the past month and -50.99 % over the last year.

About

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulat ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-12-07 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

+17.02 (+6.41%)

USD122.24B 18.38 14.64
BNTX BioNTech SE

+22.86 (+8.17%)

USD83.44B 8.87 7.65
REGN Regeneron Pharmaceuticals Inc

+10.09 (+1.61%)

USD68.31B 10.00 7.78
VRTX Vertex Pharmaceuticals Incorpo..

+0.16 (+0.08%)

USD51.82B 24.59 15.60
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BGNE BeiGene Ltd

+18.04 (+6.03%)

USD33.26B N/A N/A
SGEN Seagen Inc

+0.43 (+0.29%)

USD27.56B 55.02 44.86
GMAB Genmab A/S

+1.82 (+4.93%)

USD24.43B 55.83 6.05
ALNY Alnylam Pharmaceuticals Inc

+3.28 (+1.85%)

USD20.49B N/A N/A
IMMU Immunomedics, Inc

N/A

USD20.31B N/A N/A

ETFs Containing BTAI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -51.15% 29% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -51.15% 29% F 12% F
Trailing 12 Months  
Capital Gain -50.99% 28% F 11% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -50.99% 28% F 11% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 114.56% 89% B+ 94% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 114.56% 89% B+ 94% A
Risk Return Profile  
Volatility (Standard Deviation) 218.18% 11% F 7% F
Risk Adjusted Return 52.51% 80% B- 70% C-
Market Capitalization 0.63B 69% D+ 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.58 58% F 46% F
Price / Cash Flow Ratio -9.56 62% D- 73% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -43.68% 63% D 30% F
Return on Invested Capital -70.46% 31% F 12% F
Return on Assets -25.47% 50% F 15% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 6.59 34% F 19% F
Short Percent 9.69% 19% F 17% F
Beta 1.01 64% D 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector